Literature DB >> 22868811

Diagnostic value of HE4 for ovarian cancer: a meta-analysis.

Shuang Yu1, Hui-jie Yang, Shu-qin Xie, Yi-Xi Bao.   

Abstract

BACKGROUND: Ovarian cancer (OC) is the second most common gynecological cancer and the first cause of death from gynecological malignancy in Western Europe and the USA. While human epididymis-specific protein 4 (HE4) has been reported as a predictive diagnostic index, it has not been widely accepted because of inconsistent conclusions. The aim of this study was to evaluate the diagnostic value of HE4 systematically for ovarian cancer.
METHODS: All relevant original studies about HE4 in the diagnosis of ovarian cancer published from January 1974 to May 2011 were retrieved. By measuring methodological qualities, 12 papers were selected for this study, while 531 articles were searched. The overall diagnostic sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR-), and area under the receiver operating characteristic curve (AUC-ROC) were used to evaluate the diagnostic value of HE4 for ovarian cancer using the Meta-DiSc statistical software.
RESULTS: There were 2607 subjects included in this meta-analysis. The sensitivity, specificity, LR+ and LR- (95% confidence interval) of HE4 was 0.800 (0.770-0.827), 0.916 (0.902-0.929), 10.271 (6.982-15.109) and 0.228 (0.181-0.287), respectively. The area under the summary receiver operating characteristic (sROC) curve of HE4 was 0.946. The index of Q* was 0.885.
CONCLUSIONS: HE4 was found to be better than CA125 as an auxiliary indicator for the diagnosis of ovarian cancer in terms of better sensitivity, specificity, LR+ and LR-.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22868811     DOI: 10.1515/cclm-2011-0477

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  16 in total

1.  HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer.

Authors:  Blanca Ortiz-Muñoz; Eduardo Aznar-Oroval; Ana García García; Amparo Covisa Peris; Pilar Perez Ballestero; Marina Sanchez Yepes; Tomás Garcia Lozano; Carmen Illueca Ballester; Enrique García Garcia
Journal:  Tumour Biol       Date:  2014-04-27

2.  Serum human epididymis protein 4 levels in colorectal cancer patients.

Authors:  Yasemi N Kemal; Guzi N Demirag; Abdulkeri M Bedir; Leman Tomak; Murat Derebey; Di Lek Erdem; Ufuk Gör; Idris Yücel
Journal:  Mol Clin Oncol       Date:  2017-07-19

3.  Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis.

Authors:  Shuai Zhen; Li-Hong Bian; Li-Li Chang; Xin Gao
Journal:  Mol Clin Oncol       Date:  2014-04-16

4.  Clinical value of serum human epididymis protein 4 assay in the diagnosis of ovarian cancer: a meta-analysis.

Authors:  Zhijun Yang; Chunyin Wei; Zhaoqing Luo; Li Li
Journal:  Onco Targets Ther       Date:  2013-07-23       Impact factor: 4.147

5.  Human epididymis protein 4 in association with Annexin II promotes invasion and metastasis of ovarian cancer cells.

Authors:  Huiyu Zhuang; Mingzi Tan; Juanjuan Liu; Zhenhua Hu; Dawo Liu; Jian Gao; Liancheng Zhu; Bei Lin
Journal:  Mol Cancer       Date:  2014-11-01       Impact factor: 27.401

Review 6.  ESGO/ISUOG/IOTA/ESGE Consensus Statement on pre-operative diagnosis of ovarian tumors.

Authors:  Dirk Timmerman; François Planchamp; Tom Bourne; Chiara Landolfo; Andreas du Bois; Luis Chiva; David Cibula; Nicole Concin; Daniela Fischerova; Wouter Froyman; Guillermo Gallardo Madueño; Birthe Lemley; Annika Loft; Liliana Mereu; Philippe Morice; Denis Querleu; Antonia Carla Testa; Ignace Vergote; Vincent Vandecaveye; Giovanni Scambia; Christina Fotopoulou
Journal:  Int J Gynecol Cancer       Date:  2021-06-10       Impact factor: 3.437

7.  Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma.

Authors:  Lu Deng; Yiping Gao; Xiao Li; Mingbo Cai; Huimin Wang; Huiyu Zhuang; Mingzi Tan; Shuice Liu; Yingying Hao; Bei Lin
Journal:  J Exp Clin Cancer Res       Date:  2015-09-11

8.  Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers.

Authors:  György Sölétormos; Michael J Duffy; Suher Othman Abu Hassan; René H M Verheijen; Bengt Tholander; Robert C Bast; Katja N Gaarenstroom; Catharine M Sturgeon; Johannes M Bonfrer; Per Hyltoft Petersen; Hugo Troonen; Gian CarloTorre; Jan Kanty Kulpa; Malgorzata K Tuxen; Raphael Molina
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

9.  Postprandial increase in serum CA125 as a surrogate biomarker for early diagnosis of ovarian cancer.

Authors:  Zhuowei Gu; Yifeng He; Yue Zhang; Mo Chen; Keqi Song; Yuting Huang; Qing Li; Wen Di
Journal:  J Transl Med       Date:  2018-05-01       Impact factor: 5.531

10.  Diagnostic Accuracy of the ADNEX Model for Ovarian Cancer at the 15% Cut-Off Value: A Systematic Review and Meta-Analysis.

Authors:  Xiaotong Huang; Ziwei Wang; Meiqin Zhang; Hong Luo
Journal:  Front Oncol       Date:  2021-06-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.